Published in N Engl J Med on September 15, 2006
Prevention of Diabetes and Hypertension (PHIDIAS) | NCT00456963
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Prediabetes: a high-risk state for diabetes development. Lancet (2012) 6.42
The metabolic syndrome. Endocr Rev (2008) 5.33
A comprehensive review on metabolic syndrome. Cardiol Res Pract (2014) 3.47
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Prevention of diabetes. BMJ (2006) 2.05
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2009) 1.64
Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med (2011) 1.62
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol (2010) 1.36
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol (2012) 1.24
The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism (2011) 1.15
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes (2011) 1.13
Hypertension management and microvascular insulin resistance in diabetes. Curr Hypertens Rep (2010) 1.10
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med (2008) 1.09
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2008) 1.05
The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep (2013) 1.04
The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci (2011) 1.03
Oxidative stress in the cardiorenal metabolic syndrome. Curr Hypertens Rep (2012) 1.02
Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension. Am J Clin Nutr (2008) 1.01
Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol (2012) 1.01
Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature? J Biol Chem (2010) 1.00
Beta-blocker use for the stages of heart failure. Mayo Clin Proc (2009) 1.00
Direct inhibition by angiotensin II of insulin-dependent glucose transport activity in mammalian skeletal muscle involves a ROS-dependent mechanism. Arch Physiol Biochem (2010) 0.98
Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care (2011) 0.98
Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. J Clin Endocrinol Metab (2014) 0.97
Dysglycemia and a history of reproductive risk factors. Diabetes Care (2008) 0.97
Endothelial dysfunction potentially interacts with impaired glucose metabolism to increase cardiovascular risk. Hypertension (2014) 0.96
Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care (2011) 0.95
Waking up from the DREAM of preventing diabetes with drugs. BMJ (2007) 0.94
Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia (2011) 0.94
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol (2009) 0.94
Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis (2009) 0.91
The role of incretin therapy at different stages of diabetes. Rev Diabet Stud (2011) 0.89
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep (2013) 0.88
Thiazolidinediones: a 2010 perspective. Perm J (2010) 0.88
Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. Diabetes Care (2008) 0.88
Antihypertensive drugs and glucose metabolism. World J Cardiol (2014) 0.87
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension (2012) 0.87
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care (2011) 0.87
Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes (2014) 0.86
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract (2009) 0.86
The burden of type 2 diabetes: strategies to prevent or delay onset. Vasc Health Risk Manag (2007) 0.86
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs (2015) 0.86
Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome. J Am Soc Hypertens (2008) 0.85
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study. Cardiovasc Diabetol (2012) 0.85
Transgenic mice overexpressing Renin exhibit glucose intolerance and diet-genotype interactions. Front Endocrinol (Lausanne) (2013) 0.85
Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia (2013) 0.84
Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD. Clin J Am Soc Nephrol (2015) 0.84
Effects of aldosterone on insulin sensitivity and secretion. Steroids (2014) 0.83
Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis (2013) 0.83
Potassium and risk of Type 2 diabetes. Expert Rev Endocrinol Metab (2011) 0.83
Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. J Diabetes Investig (2011) 0.83
Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study. J Am Heart Assoc (2013) 0.83
Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension. Am J Physiol Regul Integr Comp Physiol (2015) 0.83
The association of the angiotensinogen gene with insulin sensitivity in humans: a tagging single nucleotide polymorphism and haplotype approach. Metabolism (2011) 0.83
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study. Eur J Clin Pharmacol (2007) 0.83
PPARs in the Renal Regulation of Systemic Blood Pressure. PPAR Res (2010) 0.82
Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol Cell Endocrinol (2012) 0.82
Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin (2012) 0.82
Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol (2010) 0.82
Metabolic syndrome and cardiovascular disease: challenges and opportunities. Clin Cardiol (2007) 0.82
The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle. Cardiorenal Med (2013) 0.81
Effect of eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab J (2012) 0.80
Therapeutic Challenges in Diabetes Prevention: We Have Not Found the "Exercise Pill". Clin Pharmacol Ther (2015) 0.80
Opposing effects of β blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol (2011) 0.80
Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature. Vasc Health Risk Manag (2007) 0.79
Approaches to treatment of pre-diabetes and obesity and promising new approaches to type 2 diabetes. Diabetes Care (2008) 0.79
RAS blockade for every diabetic patient: pro and con. Diabetes Care (2011) 0.79
Does renin angiotensin system blockade deserve preferred status over other anti-hypertensive medications for the treatment of people with diabetes? Ann Transl Med (2016) 0.79
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study. J Diabetes Sci Technol (2011) 0.79
Sympathoexcitation associated with Renin-Angiotensin system in metabolic syndrome. Int J Hypertens (2013) 0.79
JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial. Trials (2010) 0.79
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia (2017) 0.79
Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. Vasc Health Risk Manag (2009) 0.79
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. Cardiovasc Diabetol (2008) 0.78
Applying new evidence into practice: a need for knowledge translation. Can J Hosp Pharm (2015) 0.78
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud (2007) 0.78
Allele-specific expression of angiotensinogen in human subcutaneous adipose tissue. Hypertension (2013) 0.78
Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med (2008) 0.78
Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials. Cardiovasc J Afr (2009) 0.78
Type 2 diabetes risk in persons with dysglycemia: the Framingham Offspring Study. Diabetes Res Clin Pract (2011) 0.78
Handle Region Peptide Ameliorating Insulin Resistance but Not β Cell Functions in Male Rats Neonatally Treated with Sodium L-Glutamate. Int J Endocrinol (2013) 0.78
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope? Int J Diabetes Dev Ctries (2009) 0.77
Rationale for multiple risk intervention: the need to move from theory to practice. Vasc Health Risk Manag (2007) 0.77
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging (2010) 0.77
Chronic therapy for McArdle disease: the randomized trial with ACE inhibitor. Acta Myol (2007) 0.77
The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. Curr Cardiol Rep (2010) 0.77
Adipocyte-Specific Enhancement of Angiotensin II Type 1 Receptor-Associated Protein Ameliorates Diet-Induced Visceral Obesity and Insulin Resistance. J Am Heart Assoc (2017) 0.77
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders. Mediators Inflamm (2016) 0.77
High-cocoa polyphenol-rich chocolate improves blood pressure in patients with diabetes and hypertension. ARYA Atheroscler (2015) 0.76
Telmisartan and cardioprotection. Vasc Health Risk Manag (2011) 0.76
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med (2003) 7.25
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46